… for his abstract entitled: AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD DATA … Olga Molostova (Russian Federation) - OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE SPLIT DOSING …

… industry, and the reasons for delays in the production of CAR T-cell therapies. The first talk is by Jordi Llinares Garcia … requirements, and also inspired ways to deal with CAR-T cell programmes in terms of centre qualifications and …

… transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: … the EBMT Jakob R. Passweg et al  Manufacturing of primary CAR-NK cells in an automated system for the treatment of …

… after patients receiving Immune effector cells such as CAR-T therapy, anywhere in the patient pathway. The forum can be …

… sclerosis. Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been …

… OF CD19 IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CAR-T THERAPY Read the interview JON J. VAN ROOD AWARD  to Janaki … TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome …

… with drug shortages as well as recent developments in CAR-T in BiTE therapies.  We are confident that the programme …

… is promising, although under investigation. Application of CAR-T regs in autoimmune diseases - Matteo Doglio Matteo Doglio gave updates on ongoing studies for CAR-T regs in SLE, a very promising and rapidly evolving …

… sclerosis (SSc). Recently, novel cellular therapies (i.e. CAR-T cells, mesenchymal cells) have been successfully adopted in …

… and set limits. With the new treatment of CAR-T and other therapies, and the ever-growing requests for … because this delay means that the proper forms for CAR-T / IEC were not developed in PROMISE, and now we are …